Last reviewed · How we verify
mFOLFOXIRI Plus Bevacizumab
At a glance
| Generic name | mFOLFOXIRI Plus Bevacizumab |
|---|---|
| Also known as | Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab |
| Sponsor | Fudan University |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (PHASE3)
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases (PHASE3)
- Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases (PHASE2)
- mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases (PHASE3)
- The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |